KR920703839A - 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리 - Google Patents

신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리

Info

Publication number
KR920703839A
KR920703839A KR1019920700769A KR920700769A KR920703839A KR 920703839 A KR920703839 A KR 920703839A KR 1019920700769 A KR1019920700769 A KR 1019920700769A KR 920700769 A KR920700769 A KR 920700769A KR 920703839 A KR920703839 A KR 920703839A
Authority
KR
South Korea
Prior art keywords
sequence
rna
cdna
interest
expression unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019920700769A
Other languages
English (en)
Other versions
KR0185192B1 (ko
Inventor
가와사끼 글렌
Original Assignee
가와사끼 글렌
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가와사끼 글렌 filed Critical 가와사끼 글렌
Publication of KR920703839A publication Critical patent/KR920703839A/ko
Priority to KR1019980708672A priority Critical patent/KR100204359B1/ko
Priority to KR1019980708673A priority patent/KR100204360B1/ko
Application granted granted Critical
Publication of KR0185192B1 publication Critical patent/KR0185192B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6867—Replicase-based amplification, e.g. using Q-beta replicase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

내용 없음

Description

신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리
[도면의 간단한 설명]
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (47)

  1. (a) RNA 폴리머라제 결합 시퀀스, 리보솜 결합 시퀀스, 및 번역 개시 시그널을 함유한 5'미번역 영역으로 이루어진, mRNA를 생성할 수 있는 시험관내 발현 유니트를 조립하고; (b) 한가지 또는 그이상의 세미-랜덤 뉴클레오티드 시퀀스를 그 발현 유니트에 부착하고; (c) 발현 유니트 및 세미-랜덤 뉴클레오티드와 관련된 시퀀스를 전사하거나 복제하여 RNA를 생성하며; (d) 그 RNA를 번역하여 폴리솜을 유지하는데 충분한 조건하에 폴리솜을 생성하며; (e) 그 폴리솜을 관심 물질에 결합하고; (f) 그 관심 물질에 결합하는 그 폴리솜을 분리하며; (g) 그 분리된 폴리솜을 분쇄하여 mRNA를 유리하며; (h) 그 mRNA를 회수하고; (i) 회수된 mRNA로 부터 cDNA를 조립하고; j) 그 cDNA를 발현시켜 신규의 폴리펩티드을 생성하는 것으로 이루어진 신규 폴리펩티드의 재조방법.
  2. 제1항에 있어서, mRNA를 회수하고 cDNA를 조립하는 단계에 이어서 cDNA를 폴리머라제 사슬 반응에 의하여 확대시키는 것이 특징인 방법.
  3. 제1항에 있어서, 상기 세이-랜덤 뉴클레오티드 시퀀스가 데옥시리보핵산으로 이루어진 것이 특징인 방법.
  4. 제1항에 있어서, 상기 세미-랜덤 뉴클레오디드 시퀀스카 리보핵산으로 이루어진 것이 특징인 방법.
  5. 제1항에 있어서, 상기 발현 유니트가 적어도 한개의 RNA-지시 RNA 폴리머라제 인식 시퀀스를 함유하는 것이 특징인 방법.
  6. 제5항에 있어서, 상기 RNA-지시 RNA 폴리머라제가 Q-베타 레플리카제인 것이 특징인 방법.
  7. 제1항에 있어서, 회수 단계에 이어서 mRNA를 확대시키는 것이 특징인 방법.
  8. 제7항에 있어서, 확대 단계가 복제 시퀀스를 RNA-의존 RNA 폴리머리제로서 합성시키는 것으로 이루어진 것이 특징인 방법.
  9. 제8항에 있어서, RNA-의존 RNA 폴리머라제가 Q-베타 레플리카제인 것이 특징인 방법.
  10. 제1항에 있어서, 분리 단계가 연속 회석 또는 병류 세척 단계에 의하여 관심 물질에 결합하지 않는 폴리솜을 제거하는 것으로 이루어진 것이 특징인 방법.
  11. 제1항에 있어서, 상기 폴리솜을 분리하는 단계에 이어서, 폴리솜이 관심 물질로부터 유리되도록 선택된 엄격한 조건에 상기 폴리솜을 노출시키는 것이 특징인 방법.
  12. 제11항에 있어서, 상기 폴리솜을 노출시키는 단계가 온도를 상승시키고, 염 농도를 저하시키고, 또는 그 폴리솜의 금속이온 농도는 상승시키는 것으로 이루어진 것이 특징인 방법.
  13. (a) RNA 폴리머라제 결합 시퀀스, 리보솜 결합 시퀀스, 및 번역 개시 시그널을 함유한 5'미번역 영역으로 이루어진, mRNA를 생성한 수 있는 시험관내 발현 유니트를 조립하고; (b) 한가지 모는 그이상의 세미-랜덤 뉴클레오티드 시퀀스를 그 발현 유니트에 부착하고; (c) 발현 유니트와 세미-랜덤 뉴클레오티드와 관련된 시퀀스를 전사시켜 RNA를 생성하며; (d) 그 RNA를 번역하여 생물학적 활성 폴리펩티드를 생성하며; (e) 그 생물학적 활성 폴리펩티드를 코드화하는 RNA를 세분하고; (f) 관심 유전자가 분리되도록 단계(c)-(e)에 제시된 바와같이 전사하고, 번역하며, 세분하며; (g) 그 분리된 유전자로 부터 cDNA를 조립한 다음; (h) 그 cDNA를 발현시켜 신규 폴리펩티드를 생성하는 것으로 이루어진 신규 폴리펩티드의 제조방법.
  14. (a) RNA 폴리머라제 결합 시퀀스, 리보솜 결합 시퀀스, 및 번역 개시 시그널을 함유한 5'미번역 영역으로 이루어진, mRNA을 생성할 수 있는 시힘관내 발현 유니트를 조립하고; (b) 한가지 또는 그이상의 세미-랜덤 뉴클레오티드 시퀀스를 발현 유니트에 부착하며; (c) 발현 유니트 및 세미-랜덤 뉴클레오티드 시퀀스와 관련된 시퀀스를 복제하여 RNA를 생성하며; (d) 그 RNA를 번역하여 생물학적 활성 폴리펩티드를 생성하고; (e) 그 생물학적 활성 폴리펩티드를 코드화하는 RNA를 세분하고, (f) 관심 유전자가 분리되도록 단계 (d)-(e)에 제시된 바와같이 번역 및 세분하며; (g) 그 분리된 유전자로 부터 cDNA를 조립한 다음; (h) 그 cDNA를 발현시켜 신규의 폴리펩티드를 생성하는 것으로 이루어진 신규 폴리펩티드의 제조방법.
  15. 제14항에 있어서, RNA를 세분하는 단계에 이어서, 생물학적 활성 폴리펩티드와 관련한 신규의 유전자 시퀀스를 폴리머라제 사슬 반응물 또는 RNA-지시 RNA 폴리머라제로서 확대하는 것이 특징인 방법.
  16. 제1, 13 또는 14항의 방법에 의하여 생성된 폴리펩티드.
  17. 제1, 13 또는 14항에 있어서, 상기 리보솜 결합 부위가 성숙핵, 원시핵, 또는 비루스 리보솜 결합 시퀀스로 이루어진 것이 특징인 방법.
  18. 제1, 13 또는 14항에 있어서, 상기 리보솜 결합 시퀀스가 척추동물의 교감 번역 개시 시퀀스, GCCGCCACCATGG, 또는 작용 관련 시퀀스로 이루어진 것이 특징인 방법.
  19. 제1, 13 또는 14항에 있어서, 발현 유니트가 추가로 선택된 아미노-말단 ID 펩티드를 코드화하는, 개시 코돈에 위치한 시퀀스로 이루어진 것이 특징인 방법.
  20. 제1, 13 또는 14항에 있어서, 상기 발현 유니트가 추가로 신규 유전자의 확대, 클로닝, 복제, 정제, 및 분리를 증가시키는 시퀀스중에서 선택된 선택 시퀀스의 3'영역으로 이루어진 것이 특징인 방법.
  21. 제20항에 있어서, 상기 3' 영역이 리보솜 전위를 방해하는데 적합한 회문형 시퀀스를 포함한 것이 특징인 방법.
  22. 제20항에 있어서, 상기 3' 영역이 C-말단 ID 시퀀스를 포힘한 것이 특징인 방법.
  23. 제22항에 있어서, 상기 C-말단 ID 시퀀스가 반복 시퀀스로 이루어진 것이 특징인 방법.
  24. 제22항에 있어서, 상기 C-말단 ID 시퀀스가 항체에 결합할 수 있는 펩티드를 코드화하는 것이 특징인 방법.
  25. 제1, 13 또는 14항에 있어서, 상기 발현 유니트가 추가로 생체내에서 신규 유전자를 발현시키는데 적합한 제한 부위로 이루어진 것이 특징인 방법.
  26. 제25항에 있어서, 상기 제한 부위의 적어도 한가지가 번역 출발점에 위치한 시퀀스 CCATGG로 이루어진 것이 특징인 방법.
  27. 제1, 13 또는 14항에 있어서, 상기 발현 유니트가 T7, T3, 또는 SP6폴리머라제를 위한 촉진인자 시퀀스를 포함한 것이 특징인 방법.
  28. 제1, 13 또는 14항에 있어서, 자연 발생 DNA 또는 cDNA를 기계적, 화학적, 또는 효소적으로 단편화함으로서 세미-랜덤 뉴클레오티드 시퀀스를 발생하는 것이 특징인 방법.
  29. 제1, 13 또는 14항에 있어서, 뉴클레오티드를 화학적으로 합성하므로서 세미-랜덤 뉴클레오티드를 발생시켜 유전자 시퀀스를 형성하는 것이 특징인 방법.
  30. 제29항에 있어서, 상기 뉴클레오티드를 화학적으로 합성하는 단계는 (1) 제1코돈 위치에서 실제 동일 몰량의 C, A 및 G 그리고 실제 동일 몰량의 T에서 단지 반만 사용하고; (2) 제2코돈 위치에서 실제 동일 몰량의 C, T, 및 G. 그리고 실제 동일 몰량의 A에서 단지 반만 사용한 다음; (3) 제3코돈 위치에서 실제 동일 몰량의 C와 G 또는 T와 G를 사용하는 단계로 이루어진 것이 특징인 방법.
  31. 제1, 13 또는 14항에 있어서, 부착 단계가 추가로 발현 유니트의 5'미번역 영역의 3'말단위에 바로 상기 뉴클레오티드를 중합시키는 것으로 이루어진 것이 특징인 방법.
  32. 제1 또는 13항에 있어서, 전사 단계가 디구아노신 트리포스페이트 또는 그의 동족체의 존재하에 상기 시퀀스를 전사하는 것으로 이루어진 것이 특징인 방법.
  33. 제1, 13 또는 14항에 있어서, 번역 단계가 디구아노신 트리포스페이트 또는 그의 동족체 및 구아닐일트란스퍼라제 존재하에 상기 시퀀스를 번역하는 것으로 이루어진 것이 특징인 방법.
  34. 제1, 13 또는 14항에 있어서, 번역 단계가 무의미-억제 tRNA 존재하에 수행되는 것이 특징인 방법.
  35. 제34항에 있어서, 무의미-억제 tRNA가 티로신-삽입, 무의미-억제 tRAN인 것이 특징인 방법.
  36. 제1, 13 또는 14항에 있어서, 상기 관심 물질이 표면 항원, 수용체 단백질, 톡신, 유기 중합체, 메타볼라이트, 단백질 분자의 활성부위, 호르몬, 항체, 및 오염물질중에서 선택되는 것이 특징인 방법.
  37. 제1, 13 또는 14항에 있어서, 상기 관심 물질이 항체의 가변/과도 가변 영역인 것이 특징인 방법.
  38. 제1, 13 또는 14항에 있어서, 상기 관심 물질이 수용체 단백질인 것이 특징인 방법.
  39. 제38항에 있어서, 상기 수용체 단백질이 성장인지 수용체 단백질인 것이 특징인 방법.
  40. 39항에 있어서, 상기 성장인자 수용체 단백질이 인슐린 및 상피 성장인자중에서 선택되는 것이 특징인 방법.
  41. 제1, 13 또는 14항에 있어서, 상기 관심 물질이 비루스 표면항원, 비루스 수용체 단백질 및 CD4 중에서 선택되는 것이 특징인 방법.
  42. 제1, 13 또는 14항에 있어서, cDNA를 발현시키는 단계가 그 cDNA의 뉴클레오티드 시퀀스를 기재로한 아미노산 시퀀스를 화학적으로 합성하는 것으로 이루어진 것이 특징인 방법.
  43. 제1, 13 또는 14항에 있어서, cDNA를 발현시키는 단계가 유전공학 미생물에서 합성을 위한 발현 벡터로 뉴클레오티드 시퀀스를 클로닝하는 것으로 이루어진 것이 특징인 방법.
  44. 제1, 13 또는 14항에 있어서, cDNA를 발현시키는 단계가 뉴클레오티드 시퀀스의 시험관내 전사 및/ 또는 번역으로 이루어진 것이 특징인 방법.
  45. 제1, 13 또는 14항에 있어서, cDNA를 발현시키는 단계가 cDNA에 의하여 코드화되는 것과 실제로 동일한 폴리폡티드를 코드화하는 뉴클레오티드 시퀀스를 합성하는 것으로 이루어지며, 뉴클레오티드 시퀀스에 의하여 코드화된 폴리폡티드는 관심물질에 결합하는 폴리솜의 결합영역과 실제 동일한 것이 특징인 방법.
  46. 제1, 13 또는 14항에 있어서, 상기 cDNA을 시퀀스 코드화 톡신, 항체, 효소, 생물활성 펩티드, 및 항체에 결합할 수 있는 펩티드중에서 선택된 다른 선택 뉴클레오티드 시퀀스에 결합하는 것이 특징인 방법.
  47. RNA 폴리머라제 결합 시퀀스, 리보솜 결합 시퀀스, 번역 개시 시그널을 함유한 5'미번역 영역으로 이루어진 시험관내 발현 유니트, 및 한가지 또는 그이상의 세미-랜덤 뉴클레오티드 시퀀스를 전사시져 mRNA 라이브러리를 생성하여; 부착된 폴리펩티드 사슬을 가진 폴리솜을 유지하는 조건하에 mRNA 라이브러리를 번역하고; 관심 물질에 폴리솜을 접촉하며 관심물질에 특이하게 결합하는 폴리솜으로 부터 mRNA를 분리하는 것으로 이루어진, 관심 폴리펩티드를 코드화하는 뉴클레오티드 시퀀스의 분리방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920700769A 1989-10-05 1990-10-04 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리 Expired - Lifetime KR0185192B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1019980708672A KR100204359B1 (en) 1989-10-05 1998-10-28 Cell-free synthesis and isolation of novel gene and popyeptide
KR1019980708673A KR100204360B1 (en) 1989-10-05 1998-10-28 A method for identifying a polynucleotide molecule having a selected nucleic acid sequence from a library of random or semi-random polynucleotide molecules

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41735789A 1989-10-05 1989-10-05
US417,357 1989-10-05
US417357 1989-10-05
PCT/US1990/005682 WO1991005058A1 (en) 1989-10-05 1990-10-04 Cell-free synthesis and isolation of novel genes and polypeptides

Publications (2)

Publication Number Publication Date
KR920703839A true KR920703839A (ko) 1992-12-18
KR0185192B1 KR0185192B1 (ko) 1999-04-01

Family

ID=23653670

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1019920700769A Expired - Lifetime KR0185192B1 (ko) 1989-10-05 1990-10-04 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리
KR1019980708672A Expired - Lifetime KR100204359B1 (en) 1989-10-05 1998-10-28 Cell-free synthesis and isolation of novel gene and popyeptide
KR1019980708673A Expired - Lifetime KR100204360B1 (en) 1989-10-05 1998-10-28 A method for identifying a polynucleotide molecule having a selected nucleic acid sequence from a library of random or semi-random polynucleotide molecules

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1019980708672A Expired - Lifetime KR100204359B1 (en) 1989-10-05 1998-10-28 Cell-free synthesis and isolation of novel gene and popyeptide
KR1019980708673A Expired - Lifetime KR100204360B1 (en) 1989-10-05 1998-10-28 A method for identifying a polynucleotide molecule having a selected nucleic acid sequence from a library of random or semi-random polynucleotide molecules

Country Status (11)

Country Link
US (2) US5658754A (ko)
EP (1) EP0494955B1 (ko)
JP (2) JP3127158B2 (ko)
KR (3) KR0185192B1 (ko)
AT (1) ATE168416T1 (ko)
AU (1) AU638762B2 (ko)
CA (1) CA2067194C (ko)
DE (1) DE69032483T2 (ko)
DK (1) DK0494955T3 (ko)
ES (1) ES2118066T3 (ko)
WO (1) WO1991005058A1 (ko)

Families Citing this family (367)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747334A (en) * 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5962219A (en) * 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5795747A (en) * 1991-04-16 1998-08-18 Evotec Biosystems Gmbh Process for manufacturing new biopolymers
DE4112440C1 (ko) * 1991-04-16 1992-10-22 Diagen Institut Fuer Molekularbiologische Diagnostik Gmbh, 4000 Duesseldorf, De
WO1993003172A1 (en) * 1991-08-01 1993-02-18 University Research Corporation Systematic polypeptide evolution by reverse translation
US5783384A (en) * 1992-01-13 1998-07-21 President And Fellows Of Harvard College Selection of binding-molecules
US5648458A (en) * 1992-05-06 1997-07-15 Affymax Technologies N.V. Peptides and compounds that bind to ELAM-1
US5643873A (en) * 1992-05-06 1997-07-01 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1
US5728802A (en) * 1992-05-06 1998-03-17 Affymax Technologies N.V. Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1)
AU4843893A (en) * 1992-09-02 1994-03-29 Scripps Research Institute, The Coupled isothermal polynucleotide amplification and translation system
WO1995011922A1 (en) * 1993-10-29 1995-05-04 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5525735A (en) * 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5525734A (en) * 1994-06-22 1996-06-11 Affymax Technologies N.V. Methods for synthesizing diverse collections of pyrrolidine compounds
US5885577A (en) * 1994-09-21 1999-03-23 Cytogen Corporation Antigen binding peptides (abtides) from peptide libraries
DE69526665T2 (de) * 1994-09-21 2002-11-21 Cytogen Corp., Princeton Antigen bindende peptide (abtides) aus peptidbibliotheken
DE69530119T2 (de) * 1994-12-30 2003-09-25 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Verfahren zur kontrollierten synthese von beliebigen peptidmischungen kodierende polynukleotidmischungen
US6341256B1 (en) * 1995-03-31 2002-01-22 Curagen Corporation Consensus configurational bias Monte Carlo method and system for pharmacophore structure determination
US20010053523A1 (en) * 1995-06-02 2001-12-20 M&E Biotech A/S. Method for identification of biologically active peptides and nucleic acids
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
JP2000511050A (ja) * 1996-05-31 2000-08-29 メディジーン・アクチェンゲゼルシャフト 機能性分子表面の生成、スクリーニング、および展開のための新規の合成タンパク質の構造の鋳型
US6875620B1 (en) * 1996-10-31 2005-04-05 Agilent Technologies, Inc. Tiling process for constructing a chemical array
US8207093B2 (en) 1997-01-21 2012-06-26 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US6261804B1 (en) * 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
ATE332368T1 (de) 1997-01-21 2006-07-15 Gen Hospital Corp Selektion von proteinen mittels rns-protein fusionen
GB9703369D0 (en) * 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
GB2338237B (en) * 1997-02-18 2001-02-28 Actinova Ltd In vitro peptide or protein expression library
EP0975748B1 (en) 1997-04-23 2006-03-29 Universität Zürich Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
ES2230701T3 (es) 1997-07-07 2005-05-01 Medical Research Council Procedimiento de seleccion in vitro.
US6066460A (en) * 1997-07-24 2000-05-23 President And Fellows Of Harvard College Method for cloning secreted proteins
CA2302147C (en) * 1997-09-03 2008-05-13 Biovation Limited Methods for protein screening
US6927025B1 (en) 1997-09-03 2005-08-09 Biovation Limited Methods for protein screening
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
ES2156581T5 (es) 1998-03-30 2015-01-21 Northwest Biotherapeutics, Inc. Aplicaciones terapéuticas y diagnósticas basadas en el papel del gen CXCR-4 en la tumorigénesis
CA2323638A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US6440695B1 (en) * 1998-04-17 2002-08-27 Whitehead Institute For Biomedical Research Method for producing diverse libraries of encoded polypeptides
US6562622B1 (en) * 1998-05-08 2003-05-13 Diatech Pty, Ltd Continuous in vitro evolution
US20030170820A1 (en) * 1998-05-08 2003-09-11 Gregory Coia Continuous in- vitro evolution
GB9810756D0 (en) 1998-05-19 1998-07-15 Angeletti P Ist Richerche Bio Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
AU4854999A (en) * 1998-07-02 2000-01-24 Invitro Diagnostics, Inc. Methods, compositions and apparatus for making nucleic acid molecules having a selected affinity to a target molecule
US20100130368A1 (en) * 1998-07-30 2010-05-27 Shankar Balasubramanian Method and system for sequencing polynucleotides
US6787308B2 (en) * 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
US20040106110A1 (en) * 1998-07-30 2004-06-03 Solexa, Ltd. Preparation of polynucleotide arrays
US20030022207A1 (en) * 1998-10-16 2003-01-30 Solexa, Ltd. Arrayed polynucleotides and their use in genome analysis
US20040002101A1 (en) * 1998-08-12 2004-01-01 Proteus S.A. Method and kit for discovering nucleic acids that encode desired functions
JP2002522091A (ja) * 1998-08-17 2002-07-23 フィロス インク． ３’非翻訳領域を欠損する核酸を生成して細胞ｒｎａ蛋白質融合体形成を最適化する方法
JP4278872B2 (ja) 1998-08-17 2009-06-17 フィロス インク． 蛋白質・核酸融合分子ライブラリーを用いた化合物・蛋白質相互作用の同定
US20060088846A1 (en) 1998-08-28 2006-04-27 Michele Pagano Methods to identify compounds useful for the treatment of proliferative and differentiative disorders
NZ511699A (en) * 1998-12-02 2003-02-28 Phylos Inc DNA-protein fusions and uses thereof
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
HUP0200575A3 (en) 1999-03-25 2004-11-29 Abbott Gmbh & Co Kg Human antibodies that bind human il-12 and methods for producing
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AU5011200A (en) 1999-05-14 2000-12-05 Arbor Vita Corporation Molecular interactions in hematopoietic cells
US6623926B1 (en) 1999-06-01 2003-09-23 Phylos, Inc. Methods for producing 5′-nucleic acid-protein conjugates
US20030091999A1 (en) * 1999-10-01 2003-05-15 Zhongping Yu Compositions and methods for identifying polypeptides and nucleic acid molecules
DE60118527D1 (de) 2000-01-24 2006-05-18 Compound Therapeutics Inc Sensible und multiplexe diagnostische tests zur proteinanalyse
US7022479B2 (en) 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
CA2402452A1 (en) * 2000-03-31 2001-10-11 Cambridge Antibody Technology Limited Improvements to ribosome display
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
AU8506601A (en) 2000-08-18 2002-03-04 Dyax Corp Binding polypeptides for b lymphocyte stimulator protein (blys)
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
JP4723713B2 (ja) * 2000-09-25 2011-07-13 トヨタ自動車株式会社 ｍＲＮＡの潜在的翻訳制御因子のスクリーニング方法
US20040091509A1 (en) * 2000-12-14 2004-05-13 Avon Products, Inc. Skin care composition that mediates cell to cell communication
KR100401296B1 (ko) * 2000-12-27 2003-10-11 드림바이오젠 주식회사 수식물질에 의해 수식된 단백질 변이체 및 이것의 제조방법
JP4061043B2 (ja) 2000-12-28 2008-03-12 株式会社ポストゲノム研究所 ｉｎｖｉｔｒｏ転写／翻訳系によるペプチド等の製造方法
EP1423400B2 (en) 2001-03-19 2013-05-22 President and Fellows of Harvard College Evolving new molecular function
EP1249499A1 (de) * 2001-04-10 2002-10-16 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren und Vorrichtung zur Bestimmung und Selektion von Molekül-Molekül-Wechselwirkungen
JP2004536579A (ja) 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
EP1401850A1 (en) 2001-06-20 2004-03-31 Nuevolution A/S Nucleoside derivatives for library preparation
IL159268A0 (en) 2001-06-20 2004-06-01 Nuevolution As Templated molecules and methods for using such molecules
GB0115841D0 (en) 2001-06-28 2001-08-22 Medical Res Council Ligand
AU2002337312A1 (en) 2001-10-25 2003-05-06 Medical Research Council Molecules
GB0126887D0 (en) * 2001-11-08 2002-01-02 Univ London Method for producing and identifying soluble protein domains
GB0127564D0 (en) 2001-11-16 2002-01-09 Medical Res Council Emulsion compositions
US20030162209A1 (en) * 2001-12-19 2003-08-28 George Martin PCR based high throughput polypeptide screening
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7781396B2 (en) * 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
ATE556714T1 (de) 2002-02-01 2012-05-15 Life Technologies Corp Doppelsträngige oligonukleotide
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP1572902B1 (en) 2002-02-01 2014-06-11 Life Technologies Corporation HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US20030166010A1 (en) * 2002-02-25 2003-09-04 Affholter Joseph A. Custom ligand design for biomolecular filtration and purification for bioseperation
US10731151B2 (en) 2002-03-15 2020-08-04 Nuevolution A/S Method for synthesising templated molecules
AU2003214031A1 (en) 2002-03-15 2003-09-29 Nuevolution A/S An improved method for synthesising templated molecules
EP1572927A4 (en) 2002-04-08 2007-10-17 Pioneer Hi Bred Int REINFORCED EXTRACTION OF SILK UNDER STRESS
DE60328979D1 (de) 2002-05-10 2009-10-08 Jackson H M Found Military Med Androgen-reguliertes pmepa1 gen und verfahren zu seiner verwendung zur hemmung von krebszellwachstum
GB2406169B (en) * 2002-06-12 2006-11-01 Ambion Inc Methods and compositions relating to labeled rna molecules that reduce gene expression
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
US20100075423A1 (en) * 2002-06-12 2010-03-25 Life Technologies Corporation Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP1539980B1 (en) 2002-08-01 2016-02-17 Nuevolution A/S Library of complexes comprising small non-peptide molecules and double-stranded oligonucleotides identifying the molecules
WO2004016767A2 (en) 2002-08-19 2004-02-26 The President And Fellows Of Harvard College Evolving new molecular function
DK1534830T3 (da) 2002-09-06 2011-02-14 Isogenica Ltd In vito-peptid-ekspressionsbibliotek
JP4694840B2 (ja) 2002-09-09 2011-06-08 アルボー ビータ コーポレーション 子宮頸部癌を検査する方法
US8791053B2 (en) 2002-09-27 2014-07-29 Mpm-Holding Aps Spatially encoded polymer matrix
EP2348124B1 (en) 2002-10-30 2013-12-11 Nuevolution A/S Synthesis of a bifunctional complex
WO2004042074A2 (en) * 2002-11-04 2004-05-21 Icogenex Corporation Methods for the identification of agents that modulate the structure and processing of a membrane bound precursor protein
JP2006505272A (ja) * 2002-11-04 2006-02-16 バイオアークティック ニューロサイエンス アーベー βアミロイド前駆体タンパク質の構造およびプロセシングを調節する薬剤の同定のための方法
US7491699B2 (en) * 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
WO2004056994A2 (en) 2002-12-19 2004-07-08 Nuevolution A/S Quasirandom structure and function guided synthesis methods
ATE426575T1 (de) * 2003-01-07 2009-04-15 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
CA2513899C (en) 2003-01-29 2013-03-26 454 Corporation Methods of amplifying and sequencing nucleic acids
US20070026397A1 (en) 2003-02-21 2007-02-01 Nuevolution A/S Method for producing second-generation library
US7915201B2 (en) 2003-03-20 2011-03-29 Nuevolution A/S Ligational encoding of small molecules
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US8048627B2 (en) 2003-07-05 2011-11-01 The Johns Hopkins University Method and compositions for detection and enumeration of genetic variations
US7585815B2 (en) * 2003-07-24 2009-09-08 Lawrence Livermore National Security, Llc High throughput protein production screening
EP2824190A1 (en) 2003-09-09 2015-01-14 Integrigen, Inc. Methods and compositions for generation of germline human antibody genes
US11118215B2 (en) 2003-09-18 2021-09-14 Nuevolution A/S Method for obtaining structural information concerning an encoded molecule and method for selecting compounds
EP1663199B1 (en) * 2003-09-25 2013-04-03 Tel Aviv University Future Technology Development L.P. Compositions and methods using same for treating amyloid-associated diseases
WO2005031362A2 (en) * 2003-10-02 2005-04-07 Ramot At Tel Aviv University Ltd. Novel antibacterial agents and methods of identifying and utilizing same
EP1694693A2 (en) 2003-12-17 2006-08-30 Praecis Pharmaceuticals Inc. Methods for synthesis of encoded libraries
US7972994B2 (en) 2003-12-17 2011-07-05 Glaxosmithkline Llc Methods for synthesis of encoded libraries
EP1709084A4 (en) 2003-12-23 2008-05-28 Nono Inc POLYPEPTIDES FOR MODULATING BINDING OF TRP-CHANNEL PROTEINS AND TRP-ASSOCIATED PROTEINS
DE602005017370D1 (de) 2004-03-22 2009-12-10 Nuevolution As Ligationscodierung unter verwendung von oligonukleotidbausteinen
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US8318488B1 (en) 2004-05-11 2012-11-27 Axiogenesis Ag Assay for drug discovery based on in vitro differentiated cells
US20090156471A1 (en) * 2004-07-15 2009-06-18 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
EP1781310B1 (en) * 2004-08-02 2015-10-14 Ramot at Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
US7732479B2 (en) 2004-08-19 2010-06-08 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
WO2006027780A2 (en) * 2004-09-08 2006-03-16 Ramot At Tel Aviv University Ltd. Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
EP2371390A3 (en) 2004-10-08 2013-03-13 Domantis Limited Antagonists and methods of use therefor
KR100730875B1 (ko) 2004-12-07 2007-06-20 가부시키가이샤 시마즈세이사쿠쇼 번역반응 촉진 ｄｎａ 단편 및 그것을 사용한 무세포계단백질 합성방법
US20060142228A1 (en) * 2004-12-23 2006-06-29 Ambion, Inc. Methods and compositions concerning siRNA's as mediators of RNA interference
CA2601400A1 (en) 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
WO2006123445A1 (ja) * 2005-05-18 2006-11-23 Kyoto University タンパク質の表示方法
SI2452694T1 (sl) 2005-06-30 2019-05-31 Janssen Biotech, Inc. Protitelesa proti-IL-23, sestavki in postopki uporabe
WO2007005605A2 (en) 2005-07-01 2007-01-11 Washington University In St. Louis Phosphospecific chemokine receptor antibodies
WO2007011722A2 (en) 2005-07-15 2007-01-25 President And Fellows Of Harvard College Reaction discovery system
US20070111237A1 (en) * 2005-09-14 2007-05-17 Maurizio Zanetti Process for identifying antigenized antibodies using ribosome cell free expression system
EP1973928A2 (en) * 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Self-assembled fmoc-ff hydrogels
JP2009513135A (ja) 2005-10-28 2009-04-02 プリーシス・ファーマシューティカルズ・インコーポレイテッド エンコードされたライブラリーを用いて興味のある化合物を同定する方法
US7879212B2 (en) * 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
PT3305900T (pt) 2005-12-01 2021-10-27 Nuevolution As Métodos de codificação enzimática para síntese eficaz de bibliotecas grandes
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
WO2007081385A2 (en) 2006-01-11 2007-07-19 Raindance Technologies, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
JP2009529915A (ja) 2006-03-20 2009-08-27 ゾーマ テクノロジー リミテッド ガストリン物質に対して特異的なヒト抗体および方法
US7749957B2 (en) 2006-04-06 2010-07-06 E.I. Du Pont De Nemours And Company Clay-binding peptides and methods of use
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP2530167A1 (en) 2006-05-11 2012-12-05 Raindance Technologies, Inc. Microfluidic Devices
WO2008005290A2 (en) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Methods for testing anti-thrombotic agents
WO2008008348A2 (en) 2006-07-11 2008-01-17 Arbor Vita Corporation Method and compositions for treating stroke with fever
EP2077912B1 (en) 2006-08-07 2019-03-27 The President and Fellows of Harvard College Fluorocarbon emulsion stabilizing surfactants
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
US20110294782A1 (en) 2006-11-10 2011-12-01 Massachusetts Institute Of Technology Small molecule pak inhibitors
EP3124045A3 (en) 2006-12-20 2017-05-03 Xoma (Us) Llc Treatment of il-1 beta related diseases
KR20090100461A (ko) 2007-01-16 2009-09-23 아보트 러보러터리즈 건선의 치료방법
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
RU2476442C2 (ru) 2007-03-29 2013-02-27 Эббот Лэборетриз Кристаллические антитела против il-12 человека
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
ES2614735T3 (es) 2007-07-23 2017-06-01 Janssen Biotech, Inc. Métodos y composiciones para tratar los trastornos relacionados con fibrosis usando antagonistas de la IL-17
US7829311B2 (en) 2007-07-25 2010-11-09 E.I. Du Pont De Nemours And Company Ketosteroid isomerase inclusion body tag engineered to be acid-resistant by replacing aspartates with glutamate
US7951559B2 (en) * 2007-07-25 2011-05-31 E.I. Du Pont De Nemours And Company Recombinant peptide production using a cross-linkable solubility tag
US7678883B2 (en) * 2007-07-25 2010-03-16 E.I. Du Pont De Nemours And Company Solubility tags for the expression and purification of bioactive peptides
US7794963B2 (en) 2007-11-02 2010-09-14 E.I. Du Pont De Nemours And Company Use of tetracysteine tags in fluorescence-activated cell sorting analysis of prokaryotic cells producing peptides or proteins
CN101932712B (zh) 2007-11-20 2014-05-14 先锋国际良种公司 用于改善植物应激耐性的玉米乙烯信号转导基因及其调节
SI2391650T1 (sl) 2007-12-20 2015-03-31 Xoma (Us) Llc Postopki za zdravljenje protina
WO2009117289A2 (en) 2008-03-18 2009-09-24 Abbott Laboratories Methods for treating psoriasis
GB0806562D0 (en) 2008-04-10 2008-05-14 Fermentas Uab Production of nucleic acid
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
EP4047367A1 (en) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Method for detecting target analytes with droplet libraries
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
EP2316030B1 (en) 2008-07-25 2019-08-21 Wagner, Richard W. Protein screeing methods
KR20160116056A (ko) 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
JP2012503982A (ja) 2008-09-26 2012-02-16 ワイス・エルエルシー 適合性ディスプレイベクター系
US20100113304A1 (en) * 2008-09-26 2010-05-06 Wyeth Compatible display vector systems
ES2705714T3 (es) 2008-10-31 2019-03-26 Janssen Biotech Inc Métodos y usos de dominio de Fibronectina tipo III basado en estructuras de composiciones
CA2742969A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
RU2011126338A (ru) * 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
US20100158822A1 (en) * 2008-12-18 2010-06-24 E .I. Du Pont De Nemours And Company Peptides that bind to silica-coated particles
US20100158846A1 (en) * 2008-12-18 2010-06-24 E. I. Du Pont De Nemours And Company Hair-binding peptides
US8287845B2 (en) * 2008-12-18 2012-10-16 E I Du Pont De Nemours And Company Hair-binding peptides
US20100158837A1 (en) 2008-12-18 2010-06-24 E. I. Du Pont De Nemours And Company Iron oxide-binding peptides
WO2010074783A1 (en) 2008-12-23 2010-07-01 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
BRPI1008532B1 (pt) 2009-02-12 2021-12-14 Janssen Biotech, Inc Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos
US8716553B2 (en) 2009-03-02 2014-05-06 Pioneer Hi Bred International Inc NAC transcriptional activators involved in abiotic stress tolerance
WO2010111231A1 (en) 2009-03-23 2010-09-30 Raindance Technologies, Inc. Manipulation of microfluidic droplets
US8481678B2 (en) 2009-03-30 2013-07-09 E I Du Pont De Nemours And Company Peptide-based tooth whitening reagents
JP2012522057A (ja) * 2009-03-30 2012-09-20 ジヨンソン・アンド・ジヨンソン・コンシユーマー・カンパニーズ・インコーポレーテツド 化粧用剤の送達のためのペプチドに基づく系
US20110035843A1 (en) 2009-08-05 2011-02-10 Pioneer Hi-Bred International, Inc. Novel eto1 genes and use of same for reduced ethylene and improved stress tolerance in plants
KR101161622B1 (ko) * 2009-08-31 2012-07-04 헬릭스 주식회사 번역 효율 증진용 ｄｎａ 단편 및 이를 포함하는 재조합 벡터
SG179135A1 (en) * 2009-09-14 2012-05-30 Abbott Lab Methods for treating psoriasis
EP2480888B1 (en) 2009-09-25 2016-11-30 XOMA Technology Ltd. Screening methods
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
US10520500B2 (en) 2009-10-09 2019-12-31 Abdeslam El Harrak Labelled silica-based nanomaterial with enhanced properties and uses thereof
JP2013508287A (ja) * 2009-10-14 2013-03-07 ヤンセン バイオテツク，インコーポレーテツド 抗体を親和性成熟する方法
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
IL201999A (en) 2009-11-08 2017-10-31 Medical Res & Development Fund For Health Services Bnai Zion Medical Center The State Of Israel A knockout mouse of the 1 – mo gene, a gene associated with morbidly extreme obesity
ES2907862T3 (es) 2009-12-10 2022-04-26 Univ Columbia Activadores de histona acetiltransferasa y usos de los mismos
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
US10837883B2 (en) 2009-12-23 2020-11-17 Bio-Rad Laboratories, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
KR20130009760A (ko) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
EP4484577A3 (en) 2010-02-12 2025-03-26 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
WO2011111832A1 (ja) 2010-03-11 2011-09-15 独立行政法人理化学研究所 ポリペプチド配列の選択方法、並びに金属酸化物または含珪素化合物結合ペプチドおよびその利用
EP3540059A1 (en) 2010-04-16 2019-09-18 Nuevolution A/S Bi-functional complexes and methods for making and using such complexes
US8569227B2 (en) 2010-04-30 2013-10-29 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
JP2013535981A (ja) 2010-08-20 2013-09-19 ワイス・エルエルシー 成長因子不含適合細胞の細胞培養
US8987415B2 (en) 2010-09-07 2015-03-24 Technische Universitaet Muenchen Recombinant bacterial lipocalin blc and uses thereof
US9562897B2 (en) 2010-09-30 2017-02-07 Raindance Technologies, Inc. Sandwich assays in droplets
WO2012061537A2 (en) 2010-11-02 2012-05-10 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
EP2654428B1 (en) 2010-12-22 2018-02-14 The Trustees of Columbia University in the City of New York Histone acetyltransferase modulators and usese thereof
DE102010056289A1 (de) 2010-12-24 2012-06-28 Geneart Ag Verfahren zur Herstellung von Leseraster-korrekten Fragment-Bibliotheken
EP3412778A1 (en) 2011-02-11 2018-12-12 Raindance Technologies, Inc. Methods for forming mixed droplets
WO2012112804A1 (en) 2011-02-18 2012-08-23 Raindance Technoligies, Inc. Compositions and methods for molecular labeling
JP5948673B2 (ja) 2011-03-10 2016-07-06 ジーンフロンティア株式会社 リポ多糖混入量を低減した蛋白質合成用組成物、該組成物を用いた蛋白質製造方法
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US20120301904A1 (en) 2011-04-26 2012-11-29 Prosetta Antiviral, Inc Multiprotein assemblies
JP6057297B2 (ja) 2011-05-23 2017-01-11 国立研究開発法人理化学研究所 核酸構築物、核酸−蛋白質複合体、及びその利用
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
EP3216872B1 (en) 2011-06-02 2020-04-01 Bio-Rad Laboratories, Inc. Enzyme quantification
CN103732623B (zh) 2011-06-03 2017-09-29 佐马技术有限公司 对TGF‑β具有特异性的抗体
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
CN103930165B (zh) 2011-09-02 2018-05-25 纽约市哥伦比亚大学理事会 用以治疗肥胖症的代谢紊乱的CaMKII、IP3R、钙调神经磷酸酶、P38和MK2/3抑制剂
ME03008B (me) 2011-09-19 2018-10-20 Axon Neuroscience Se Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti
JP6440496B2 (ja) 2011-09-27 2018-12-19 ヤンセン バイオテツク，インコーポレーテツド 選択的結合表面を有するフィブロネクチンｉｉｉ型反復ベースのタンパク質スカフォールド
RU2663794C2 (ru) 2011-10-21 2018-08-09 Пфайзер Инк. Добавление железа для улучшения культивирования клеток
BR112014009968A2 (pt) 2011-10-25 2017-07-04 Du Pont método para redução do teor de acetato, arabinosidase e/ou ferulato em uma planta, método de modulação da concentração de carboidratos da planta em uma planta transgénica, método para alterar o teor de acetila e de reticulação nos tecidos das plantas, método para a produção de biomassa para a produção de biocombustíveis ou silagem, produto, forragem de planta
WO2013096516A1 (en) 2011-12-19 2013-06-27 Xoma Technology Ltd. Methods for treating acne
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2657334B1 (en) 2012-04-26 2016-07-06 GeneFrontier Corporation Efficient method for displaying protein multimer
WO2013172954A1 (en) 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc Peptide and peptidomimetic inhibitors
GB201214029D0 (en) * 2012-08-07 2012-09-19 Queen Mary & Westfield College method
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
MX361088B (es) 2012-11-21 2018-11-26 Janssen Biotech Inc Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos.
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
WO2014152031A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Ribonucleic acid purification
BR112015023703A2 (pt) 2013-03-15 2017-07-18 Pioneer Hi Bred Int modulação de expressão de deaminase de acc
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
EP2971165A4 (en) 2013-03-15 2016-11-23 Moderna Therapeutics Inc DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
WO2014152027A1 (en) * 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
CA2917348A1 (en) 2013-07-11 2015-01-15 Moderna Therapeutics, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
BR112016008125B1 (pt) 2013-10-14 2023-11-21 Janssen Biotech, Inc. Domínio proteico isolado de fibronectina tipo iii modificado com cisteína, seu método de produção e método para produzir uma molécula isolada de de fibronectina tipo iii biespecífica modificada com cisteína
US9309314B2 (en) 2013-12-03 2016-04-12 Agency For Science, Technology And Research (A*Star) Polypeptides, nucleic acids and uses thereof
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
WO2015097536A2 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments
WO2015103367A1 (en) 2013-12-31 2015-07-09 Raindance Technologies, Inc. System and method for detection of rna species
US10544395B2 (en) 2014-03-19 2020-01-28 Pfizer Inc. Method of cell culture
EP3973994A1 (en) 2014-06-12 2022-03-30 RA Pharmaceuticals, Inc. Modulation of complement activity
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
JP6655074B2 (ja) 2014-06-20 2020-02-26 ジェネンテック， インコーポレイテッド シャガシンに基づく足場組成物、方法及び使用
US10407683B2 (en) 2014-07-16 2019-09-10 Modernatx, Inc. Circular polynucleotides
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
US10711067B2 (en) 2015-03-03 2020-07-14 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
EP3770171A1 (en) 2015-04-03 2021-01-27 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
WO2016172485A2 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
US10844111B2 (en) 2015-05-06 2020-11-24 Janssen Biotech, Inc. Prostate specific membrane antigen binding fibronectin type III domains
CA2990360C (en) 2015-06-24 2024-02-13 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
CA2994841A1 (en) 2015-08-06 2017-02-09 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
EP3350333B2 (en) 2015-09-17 2025-08-06 ModernaTX, Inc. Polynucleotides containing a stabilizing tail region
JP7001585B2 (ja) 2015-09-23 2022-02-04 ファイザー・インク 細胞および細胞培養の方法
RU2733720C2 (ru) 2015-12-16 2020-10-06 Ра Фармасьютикалз, Инк. Модуляторы активности комплемента
WO2017137830A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
CN109071653A (zh) 2016-03-29 2018-12-21 詹森生物科技公司 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣
WO2017175086A1 (en) 2016-04-05 2017-10-12 Pfizer Inc. Cell culture process
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
SG11201810687SA (en) 2016-06-03 2018-12-28 Janssen Biotech Inc Serum albumin-binding fibronectin type iii domains
MA45412A (fr) 2016-06-21 2021-05-26 Janssen Biotech Inc Molécules de liaison au domaine de fibronectine de type iii modifiées par la cystéine
WO2017223176A1 (en) 2016-06-24 2017-12-28 Modernatx, Inc. Methods and apparatus for filtration
EP3475706B1 (en) 2016-06-27 2021-08-11 Juno Therapeutics, Inc. Mhc-e restricted epitopes, binding molecules and related methods and uses
US20200182884A1 (en) 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
WO2018014039A1 (en) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Chimeric antigen receptors (cars) specific for muc1 and methods for their use
RU2019104074A (ru) 2016-07-15 2020-08-18 Посейда Терапьютикс, Инк. Химерные рецепторы антигенов и способы их применения
CN109803680B (zh) 2016-08-01 2024-05-17 佐马美国有限公司 甲状旁腺激素受体1(pth1r)抗体和其用途
MA46236A (fr) 2016-09-14 2019-07-24 Janssen Biotech Inc Récepteurs antigéniques chimériques comprenant des domaines de la fibronectine de type iii spécifiques du bcma, et utilisations correspondantes
AU2017335771A1 (en) 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
CA3037961A1 (en) 2016-09-30 2018-04-05 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
US11208474B2 (en) 2016-11-16 2021-12-28 Janssen Biotech, Inc. Method of treating psoriasis with anti-IL23 specific antibody
KR20190093196A (ko) 2016-12-07 2019-08-08 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
CN110225770B (zh) 2016-12-14 2022-04-26 杨森生物科技公司 结合cd8a的纤连蛋白iii型结构域
EP3354736B1 (en) * 2017-01-25 2020-07-01 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Promoter construct for cell-free protein synthesis
WO2018140121A1 (en) 2017-01-30 2018-08-02 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
MX2019009377A (es) 2017-02-07 2019-12-11 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
CN117959418A (zh) 2017-03-13 2024-05-03 波赛达治疗公司 用于选择性消除和替换造血干细胞的组合物和方法
WO2018167621A1 (en) 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
AU2018329741B2 (en) 2017-09-08 2025-02-20 Poseida Therapeutics, Inc. Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
JP2020533983A (ja) 2017-09-15 2020-11-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 目的のポリペプチドのラージスケールの製造間のオンラインバイオマス静電容量モニタリング
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
JP2021502349A (ja) 2017-11-06 2021-01-28 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法
US12415844B2 (en) 2017-12-20 2025-09-16 Poseida Therapeutics, Inc. BCMA specific VCAR compositions and methods for use
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
MX2020009265A (es) 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
JP7462566B2 (ja) 2018-03-16 2024-04-05 ブリストル－マイヤーズ スクイブ カンパニー タンパク質生産の間の代謝酵素活性およびジスルフィド結合還元
US20190345245A1 (en) 2018-05-11 2019-11-14 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
US20200025776A1 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
IL326284A (en) 2018-09-24 2026-04-01 Janssen Biotech Inc A safe and effective method for treating ulcerative colitis with an anti-IL12/IL23 antibody
IL283192B2 (en) 2018-11-20 2025-10-01 Janssen Biotech Inc A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody
EP3891292A1 (en) 2018-12-06 2021-10-13 Pfizer Inc. Cells with reduced inhibitor production and methods of use thereof
MA54562A (fr) 2018-12-18 2021-10-27 Janssen Biotech Inc Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
CA3124103A1 (en) 2018-12-20 2020-06-25 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
JP7689074B2 (ja) 2019-01-15 2025-06-05 ヤンセン バイオテツク，インコーポレーテツド 若年性特発性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
WO2020152544A1 (en) 2019-01-23 2020-07-30 Janssen Biotech, Inc. Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
SG11202107720UA (en) 2019-01-31 2021-08-30 Agency Science Tech & Res Cnx/erp57 inhibitor for use in the treatment or prevention of cancer
EP3938384A4 (en) 2019-03-14 2022-12-28 Janssen Biotech, Inc. PREPARATION PROCEDURES FOR THE PREPARATION OF ANTI-IL12/IL23 ANTIBODY COMPOSITIONS
WO2020183269A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
EA202192505A1 (ru) 2019-03-14 2022-03-29 Янссен Байотек, Инк. Способы получения композиций антитела к фно
KR20210141998A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물의 제조 방법
JP2022526493A (ja) 2019-03-18 2022-05-25 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体を用いた小児被験者の乾癬の治療方法
BR112021021673A2 (pt) 2019-05-09 2021-12-21 Genentech Inc Método para melhorar o emparelhamento preferencial de uma cadeia pesada e uma cadeia leve de um anticorpo e anticorpo
JP7805788B2 (ja) 2019-05-23 2026-01-26 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
JP2022536279A (ja) 2019-06-03 2022-08-15 ヤンセン バイオテツク，インコーポレーテツド 乾癬性関節炎を治療するための抗ｔｎｆ抗体組成物及び方法
MX2021014882A (es) 2019-06-03 2022-03-25 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa.
JP2022535411A (ja) 2019-06-04 2022-08-08 ラ ファーマシューティカルズ インコーポレイテッド 補体阻害剤による炎症性疾患治療
MA56124A (fr) 2019-06-04 2022-04-13 Janssen Biotech Inc Méthode sûre et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps spécifique anti-il23
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
US20220372105A1 (en) 2019-09-05 2022-11-24 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
CN119119240A (zh) 2019-10-14 2024-12-13 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
CN115175691B (zh) 2019-12-18 2026-02-10 Aro生物疗法公司 结合血清白蛋白的纤连蛋白iii型结构域及其应用
AU2020407235A1 (en) 2019-12-20 2022-07-07 Poseida Therapeutics, Inc. Anti-MUC1 compositions and methods of use
WO2021183795A1 (en) 2020-03-11 2021-09-16 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
WO2021211628A1 (en) 2020-04-14 2021-10-21 Poseida Therapeutics, Inc. Compositions and methods for use in the treatment of cancer
US20210347880A1 (en) 2020-05-05 2021-11-11 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
IL298389A (en) 2020-05-21 2023-01-01 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
WO2022013745A1 (en) 2020-07-13 2022-01-20 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
US20220073603A1 (en) 2020-07-30 2022-03-10 Janssen Biotech, Inc. Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
US20240000969A1 (en) 2020-10-21 2024-01-04 Poseida Therapeutics San Diego Compositions and methods for delivery of nucleic acids
EP4305062A1 (en) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
IL305802A (en) 2021-03-12 2023-11-01 Janssen Biotech Inc A safe and effective method for the treatment of rheumatoid arthritis with a specific anti-IL23 antibody
EP4323008A4 (en) 2021-04-14 2026-02-25 Aro Biotherapeutics Company FN3-ARNSI DOMAIN CONJUGATES AND THEIR USES
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
US12534524B2 (en) 2021-07-09 2026-01-27 Janssen Biotech, Inc. Manufacturing methods for producing anti-TNF antibody compositions
EP4367136A1 (en) 2021-07-09 2024-05-15 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
JP2024527581A (ja) 2021-07-09 2024-07-25 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体組成物を生産するための製造方法
EP4413141A1 (en) 2021-10-04 2024-08-14 Poseida Therapeutics, Inc. Transposon compositions and methods of use thereof
EP4423126B1 (en) 2021-10-29 2026-05-06 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
WO2023079058A1 (en) 2021-11-05 2023-05-11 Yokogawa Insilico Biotechnology Gmbh Cell culture with reduced production of lactate
EP4433501A1 (en) 2021-11-15 2024-09-25 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
US20250099383A1 (en) 2022-01-21 2025-03-27 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
JP2025512860A (ja) 2022-03-30 2025-04-22 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３に特異的な抗体によって軽度から中等度の乾癬を治療する方法
EP4526342A1 (en) 2022-05-18 2025-03-26 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
AU2023383916A1 (en) 2022-11-22 2025-07-10 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
WO2024218706A1 (en) 2023-04-21 2024-10-24 Pfizer Inc. Improved cells and cell cultures
TW202448509A (zh) 2023-05-12 2024-12-16 美商建南德克公司 減少抗體黏度之方法及組成物
WO2025160432A1 (en) 2024-01-26 2025-07-31 Poseida Therapeutics, Inc. Methods and compositions for enhancing in vivo persistence and potency of cell therapy
CA3249015A1 (en) 2024-03-20 2025-10-31 Janssen Biotech, Inc. Methods of treating crohn’s disease with anti-il23 specific antibody
WO2025262604A1 (en) 2024-06-17 2025-12-26 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
CA3258952A1 (en) 2024-06-27 2026-03-01 Janssen Biotech, Inc. Methods of treating ulcerative colitis with anti-il23 specific antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710464A (en) * 1984-09-27 1987-12-01 Eli Lilly And Company Transcription terminators
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
ZA862334B (en) * 1985-03-28 1987-11-25 Cetus Corp Process for amplifying,detecting and/or cloning nucleic acid sequences
DE229046T1 (de) * 1985-03-30 1987-12-17 Marc Genf/Geneve Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences

Also Published As

Publication number Publication date
KR0185192B1 (ko) 1999-04-01
EP0494955A4 (en) 1992-08-12
ES2118066T3 (es) 1998-09-16
US5643768A (en) 1997-07-01
DE69032483D1 (de) 1998-08-20
CA2067194A1 (en) 1991-04-06
JP2001078787A (ja) 2001-03-27
DK0494955T3 (da) 1998-10-26
AU638762B2 (en) 1993-07-08
EP0494955A1 (en) 1992-07-22
US5658754A (en) 1997-08-19
KR100204359B1 (en) 1999-06-15
JP3127158B2 (ja) 2001-01-22
EP0494955B1 (en) 1998-07-15
AU6537390A (en) 1991-04-28
KR100204360B1 (en) 1999-06-15
ATE168416T1 (de) 1998-08-15
WO1991005058A1 (en) 1991-04-18
CA2067194C (en) 2003-03-18
DE69032483T2 (de) 1998-11-26
JPH05503000A (ja) 1993-05-27

Similar Documents

Publication Publication Date Title
KR920703839A (ko) 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리
US6429301B1 (en) Use of a ribozyme to join nucleic acids and peptides
US6312927B1 (en) Methods for producing nucleic acids lacking 3'-untranslated regions and optimizing cellular RNA-protein fusion formation
US6143503A (en) Use of a ribozyme to join nucleic acids and peptides
KR100566859B1 (ko) Ｒｎａ-단백질 융합물을 이용한 단백질의 선별
KR100713953B1 (ko) Ｒｎａ-단백질 융합체를 이용한 단백질의 선별
EP0590689B1 (fr) Procédé d'obtention d'ADN, ARN, peptides, polypeptides ou protéines, par une technique de recombinaison d'ADN
RU99118585A (ru) Отбор белков с использованием рнк-пептидных гибридов
CN110637086B (zh) Rna分子与肽的复合体的制造方法及其利用
KR960705041A (ko) Tgf 수용체 족 및/ 또는 bmp 수용체 족에 속하는 액티빈 수용체 유사 키나제(alk) (activin receptors-like kinase (alk), belonging to the tgf receptor family and/or to the bmp receptor family)
JPH09500007A (ja) 新規化合物生成に関するランダム化学
JPWO2012074129A1 (ja) 安定化された二次構造を有するペプチド、及びペプチドライブラリー、それらの製造方法
WO2012074130A1 (ja) ペプチドライブラリーの製造方法、ペプチドライブラリー、及びスクリーニング方法
Zoller New recombinant DNA methodology for protein engineering
WO1998014591A1 (en) Novel expression vectors for production of foreign proteins as soluble forms
US7846694B2 (en) Process for producing template DNA and process for producing protein in cell-free protein synthesis system with the use of the same
US20020137146A1 (en) Novel expression vectors for production of foreign proteins as soluble forms
WO2000018881A9 (en) Intein mediated peptide ligation
JPS5944399A (ja) 新規ｄｎａ
WO2003062417A1 (fr) Produit de ligation arn-adn, et utilisation correspondante
JPWO2003014734A1 (ja) 物質と蛋白質との間の相互作用の検出方法、物質と相互作用する蛋白質のスクリーニング方法、及び、物質とその物質と相互作用する蛋白質との複合体の形成方法
AU2004200998B2 (en) Methods for producing nucleic acids lacking 3'-untranslated regions and optimizing cellular RNA-protein fusion formation
JP2561060B2 (ja) 改良型ｒｎアーゼｔ１
JPH0714350B2 (ja) ｃ−ラス合成遺伝子類セグメント

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19920404

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19951004

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19920404

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19980528

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19981117

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19981223

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19981223

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20011220

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20021213

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20031215

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20041216

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20051219

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20060906

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20070910

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20080728

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20090730

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20090730

Start annual number: 12

End annual number: 12

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20110709

Termination category: Expiration of duration